Drug Profile
LIF - StemGen
Alternative Names: HS 217Latest Information Update: 05 Apr 2023
Price :
$50
*
At a glance
- Originator StemGen
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 28 Mar 2023 Phase-I clinical trials in Glioblastoma (unspecified route) before March 2023 (StemGen pipeline, March 2023)
- 28 Mar 2023 StemGen plans a phase II trial for Glioblastoma in unknown location (StemGen pipeline, March 2023)
- 08 Aug 2016 Suspended - Preclinical for Glioblastoma in Italy (unspecified route)